Stem Cell Clinic

The Canine Stem Cell Therapy Market To Go Strong With 4.2% CAGR Between 2026 – Crypto Daily

New York City, United States The change during the COVID-19 pandemic has overhauled our dependence on pattern setting developments, for instance, expanded reality, computer generated reality, and the Healthcare web of things. The unfulfilled cash related targets are persuading the relationship to grasp robotization and forefront advancements to stay ahead in the market competition. Associations are utilizing this open entryway by recognizing step by step operational needs and showing robotization in it to make an automated structure as far as might be feasible.

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

About- Persistence Market Research (Healthcare)

Unprecedented access to a world of information has given rise to the empowered, albeit distrustful, consumer. So is the case with healthcare, where the patient has been rendered more informed and conscientious thanks to the extraordinary penetration of the Internet. The discerning patient now demands more affordable, sophisticated, transparent, and personalized healthcare services, creating the need for new models for care.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes

Read the original here:
The Canine Stem Cell Therapy Market To Go Strong With 4.2% CAGR Between 2026 - Crypto Daily

Global Cord Blood Banking Market Is Expected to Reach USD 25.90 billion by 2027 : Fior Markets – GlobeNewswire

September 29, 2020 04:00 ET | Source: Fior Markets

Newark, NJ, Sept. 29, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, theglobal cord blood banking market is expected to grow from USD 16.88 billion in 2019 and to reach USD 25.90 billion by 2027, growing at a CAGR of 5.5% during the forecast period 2020-2027.

The global cord blood banking market is witnessing significant growth from recent years. This growth is attributed to the rising awareness about therapeutic applications of cord blood, government initiatives and funding in developed economies, increasing prevalence of life-threatening genetic diseases, and growing clinical trials in regenerative medicines. A growing number of investors and genetic disorders will propel the market for cord blood banking.

The blood that stays in the placenta and umbilical cord post-delivery is known as cord blood. A process of collecting the cord blood and cryogenically freezing and extracting the stem cells and other cells of the immune system for the potential future medical use is known as cord blood banking. It consists of a rich source of stem cells that can treat various genetic diseases. A very small amount of cord blood can be collected from a single umbilical cord. These umbilical cord contain a large number of stem cells and is only the type of stem cells stored for future use. The medical use of stem cells and immune system cells in cord blood is expanding rapidly. The cord blood banking process includes the collection process through storage and newborn stem cells for future medical purposes.

The global cord blood banking market is expected to witness significant growth, owing to the increasing number of facilities, increasing use of cord blood in the treatment of chronic diseases, and rising prevalence of chronic diseases. The factors restraining the market growth are lack of uniformity in regulatory policies, large out-of-pocket expenditure, and low acceptance rate in developing countries. Increasing research concerns about cord blood application for the treatment of genetic and idiopathic disorders will provide market growth opportunities.

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/418891/request-sample Key players operating in global cord blood banking market are CBR Systems, Singapore Cord Blood Bank, Cryo-Save, ViaCord LLC, Global Cord Blood Corporation, Jeevan Stem Cell Foundation, LifeCell, Cordlife, Americord, and FamiCord. To gain a significant market share in the global cord blood banking market, the key players are now focusing on adopting strategies such as product innovations, mergers & acquisitions, recent developments, joint venture, collaborations, and partnership. FamiCord and Cryo-Save are the major players operating in cord blood banking.

Public cord blood bank segment dominated the market and held the largest market share of 58.2% in the year 2019 On the basis of type of bank, the global cord blood banking market is segmented into public and private. Public cord blood bank segment dominated the market and held the largest market share of 58.2% in the year 2019. This growth is attributed to various funding initiatives, and various government initiatives for encouraging expectant mothers to donate cord blood cells in public banks. The private cord blood banks are expected to witness significant growth, owing to the growing awareness among expectant parents and high demand to safeguard the health of family members.

Storage segment dominated the market and held the largest market share of 51.26% in the year 2019 On the basis of services, the global cord blood banking market is segmented into processing and storage. Storage segment dominated the market and held the largest market share of 51.26% in the year 2019. This growth is attributed to the increasing number of expectant parents utilizing the preservation of newborn cord blood cells. The processing segment is expected to witness significant growth due to various technological advancements in cord blood processing methods.

Blood disorders segment dominated the market and held the largest market share of 26.7% in the year 2019 On the basis of application, the global cord blood banking market is segmented into cancer, blood disorders, immuno-deficiency disorders, metabolic disorders, and bone marrow failure syndrome. Blood disorders segment dominated the market and held the largest market share of 26.7% in the year 2019. This growth is attributed to the increasing application of cord blood cells in the treatment of blood disorders and the increasing prevalence of beta-thalassemia. Immuno-deficiency disorders are expected to witness significant growth, owing to the rapid and reliable recovery of immune function, low viral transmission rate, and low risk of graft versus host diseases.

Research institute segment dominated the market and held the largest share of 41.5% in the year 2019 On the basis of end-user, the global cord blood banking market is segmented into hospitals, research institutes, and specialty clinics. Research Institute segment dominated the market and held the largest share of 41.5% in the year 2019. This growth is attributed to the growing pervasiveness of genetic disorders and growth in the number of clinical trials for exploring new diseases. Hospitals segment is expected to witness significant growth, owing to the advancement in cord blood banking, increasing prevalence of genetic diseases.

Browse full report with TOC athttps://www.fiormarkets.com/report/cord-blood-banking-market-by-type-of-bank-418891.html

Regional Segment of Cord Blood Banking Market

On the basis of geography, the global cord blood banking market is classified into North America, Europe, Asia-Pacific, Middle East & Africa, and South America. North America held the major share of 25.8% in the year 2019. This growth is attributed to the presence of a large number of genetic disorders, continuous efforts by the researchers to explore new therapeutic applications of cord blood cells. The Asia-Pacific region market is anticipated to witness significant growth, owing to the growth potential in emerging economies like China and India due to the higher birth rate.

Request for Customization:https://www.fiormarkets.com/enquiry/request-customization/418891

About the report: The global cord blood banking market is analysed on the basis of value (USD billion). All the segments have been analysed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insights of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, and competitors position grid analysis.

For Instant Purchase:https://www.fiormarkets.com/checkout.html?reportid=418891&type=single

Customization of the Report:

The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

About Fior Markets

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.

Contact Us

Avinash D Head of Business Development Phone:+1-201-465-4211 Email:sales@fiormarkets.com Web:www.fiormarkets.com

To Read Top Industries Reports, Visit our Affiliated Website: https://www.marketquest.biz

Related Reports

Antimicrobial Susceptibility Test Market - https://www.fiormarkets.com/report/antimicrobial-susceptibility-test-market-byproduct-consumables-automated-laboratory-418813.html Autologous Cell Therapy Market - https://www.fiormarkets.com/report/autologous-cell-therapy-market-by-source-bone-marrow-418814.html Autosampler Market - https://www.fiormarkets.com/report/autosampler-market-by-product-autosampler-systems-autosampler-accessories-418815.html Surgical Sealants and Adhesives Market - https://www.fiormarkets.com/report/surgical-sealants-and-adhesives-market-by-type-synthetic-418858.html

Read the original:
Global Cord Blood Banking Market Is Expected to Reach USD 25.90 billion by 2027 : Fior Markets - GlobeNewswire

Developments In Stem Cell Therapy Market Top Regions, Countries, Sales, Revenue, Leading Companies, Types, Demand, And Forecast Assessment – The Daily…

"The niche and established Stem Cell Therapy Market 2020 Covering Prime Players, Regions, Countries, And Growth Trends Forecast To 2026 is studied in this research report. The Industry dynamics with Stem Cell Therapy future-proofing business plans are analyzed to offer sustainable growth for our clients. The insights-driven data covering the Stem Cell Therapy competition, product demand across different operating regions, countries, and a variety of applications are covered. Actionable insights offered by Reports Check will help achieve you in achieving exemplary growth with feasible investments. To strengthen the position in the global and domestic Stem Cell Therapy Market revenue, size & share analysis, import-export details, production capacity, and utilization ratio is offered.

Stem Cell Therapy Market is expected to reach XX.XX Mn USD by 2026 and it will capture lucrative opportunities with rising demand. The market dynamics, SWOT analysis, Porters Analysis, the risk assessment will create discerning growth and profit-driven strategies. Reports Checks analyst team is fine-tuned to answer all client queries and well as to deliver custom solutions based on their requirements.

Click Here To Receive FREE Sample Report Copy Or Send Any Custom Query/Requirements:https://www.reportscheck.com/shop/2021-2026-report-on-global-stem-cell-therapy-market-by-player-region-type-application-and-sales-channel/#sample-request

Study Period: 2015-2026

Base Year: 2019

Estimated Year With COVID-19 Impact Analysis:2020

Forecast Period Duration:2020-2026

Historical Period Duration:2015-2018

Important and Top Product Types:

Autologous Allogeneic

By Various Applications:

Musculoskeletal Disorder Wounds & Injuries Cornea Cardiovascular Diseases Others

By Top Companies On Global, Regional And Country Level:

Osiris Therapeutics NuVasive Chiesi Pharmaceuticals JCRPharmaceutical Pharmicell Medi-post Anterogen Molmed Takeda (TiGenix)

By Geographical Stem Cell Therapy Industry Presence:

The current Stem Cell Therapy Market landscape, detailed insights, and market drivers with restraints and trends are studied in this report. The detailed market performance during the forecast period is presented in this report. The Y-o-Y growth and CAGR is presented in this report to support the readers in making appropriate business plans. The quantitative development opportunities and innovations in Stem Cell Therapy Industry are presented.

Click Here To Check Detailed Report Table of Contents With List of Figures/ Tables and Receive FREE Sample Report:https://www.reportscheck.com/shop/2021-2026-report-on-global-stem-cell-therapy-market-by-player-region-type-application-and-sales-channel/#table-of-contents

All details including Stem Cell Therapy market investors, manufacturers, service providers, distributors, stakeholders are provided. This research study by Reports Check helps the industry experts, researchers, investors, and business aspirants. The macro and microeconomic factors with substantive Stem Cell Therapy insights are analyzed in this study.

All the above queries are effectively addressed by the analyst team of Reportscheck.com. Also, custom reports are available based on the client's requirements. Analyst views and opinions about the Stem Cell Therapy industry with qualitative and quantitative inputs will lead to sound business plans. The investment feasibility check, the latest innovations, developments, raw materials, and Stem Cell Therapy consumer demand analysis is conducted. The competitive dashboard reflects the top companies' analysis, growth rate, revenue, market share, product portfolio, and the latest developments.

Development trends, competitive analysis, and growth dynamics are key aspects of this report

Past, present, and forecast Stem Cell Therapy industry evaluation with complete performance monitoring of top players,.

Each product type and application regional and country-level bifurcation offer comprehensive and niche Stem Cell Therapy analysis

The product portfolio, Stem Cell Therapy company profiles, SWOT, and Porters Five Forces analysis offers quality inputs

Pre and Post pandemic situations, ways to overcome pandemic, Stem Cell Therapy developments across different macro and micro-segments are analyzed

Market size, product pricing analysis, Stem Cell Therapy cost structures, raw material, and downstream buyers analysis is conducted

In-depth primary and secondary techniques applied by Reports Check provide quality, reliability, thorough analysis, and competitive market intelligence

Forecast regional, country-level dynamics, expected growth rate, revenue generation, upcoming segments, and Stem Cell Therapy vendors, R&D status is specified

Browse our recently released reports here:https://www.reportscheck.com/shop/2021-2026-report-on-global-stem-cell-therapy-market-by-player-region-type-application-and-sales-channel/

Contact Us:

Olivia Martin

Marketing Manager

Email: [emailprotected]

Website:www.reportscheck.com

Here is the original post:
Developments In Stem Cell Therapy Market Top Regions, Countries, Sales, Revenue, Leading Companies, Types, Demand, And Forecast Assessment - The Daily...

Global Stem Cell Therapy for Osteoarthritis Industry 2020 Market Research With Size, Growth, Manufacturers, Segments And 2026 Forecasts Research – The…

The global Stem Cell Therapy for Osteoarthritis market report by Dataintelo provides a detailed analysis of the area marketplace expanding; competitive landscape; global, regional, and country-level market size; market growth analysis; market share; opportunities analysis; product launches; recent developments; sales analysis; segmentation growth; technological innovations; and value chain optimization. The report offers a comprehensive list of key players, their strategies they adopt to sustain in the market. All of this and more information is covered in XXX pages.

The Coronavirus (COVID-19) pandemic has affected every aspect of life worldwide. It has forced various industries to re-evaluate their strategies and adopt new ones to sustain during these trying times. The latest report includes the current COVID-19 impact on the market.

Get PDF Sample Brochure: https://dataintelo.com/request-sample/?reportId=80747

The Global Stem Cell Therapy for Osteoarthritis Market report is a comprehensive analysis of the current and future analysis, which is based on historic data. This provides the reader with quantified data, enabling them to take well informed business decisions. The report has been written using primary and secondary research. It includes predictive analysis, Porters 5 force analysis, SWOT analysis, and real-time analytics. Several graphs have been provided to support the data and for a clear understanding of various facts and figures.

The report has been divided into product types, application, end-users, and regions. These segments provide accurate calculations and forecasts for sales in terms of volume and value. This analysis can help customers increase their business and to take calculated decisions.

The Global Stem Cell Therapy for Osteoarthritis Market Report has been Segments into:

Global Stem Cell Therapy for Osteoarthritis Market Size & Share, By Product Types,

Monotherapy Combination Therapy

Global Stem Cell Therapy for Osteoarthritis Market Size & Share, By Applications,

Osteoarthritis (unspecified) Knee Osteoarthritis Shoulder Osteoarthritis Hip Osteoarthritis

Global Stem Cell Therapy for Osteoarthritis Market Size & Share, By Regions and Countries/Sub-regions,

Customize Report and Inquiry for The Stem Cell Therapy for Osteoarthritis Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=80747

The regional analysis segment is a highly comprehensive part of the report on the global Stem Cell Therapy for Osteoarthritis market. This section offers information on the sales growth in these regions on a country-level Stem Cell Therapy for Osteoarthritis market.

The historical and forecast information provided in the report span between 2018 and 2026. The report provides detailed volume analysis and region-wise market size analysis of the market.

The key players covered in this study

Mesoblast Regeneus U.S. Stem Cell Anterogen Asterias Biotherapeutics

Competitive Landscape of the Stem Cell Therapy for Osteoarthritis Market

The chapter on competitive landscape provides information about key company overview, global presence, sales and revenue generated, market share, prices, and strategies used.

Our analysts engage in extensive primary and secondary research to cull out in-depth and authentic information. Primary research includes gathering information from official government and company websites, journals, and reports. Secondary research includes interviews conducted with VPs, chairmen, directors, and other distinguished sales managers.

Contact our sales team who will guarantee you to get a customized report that suits your specific needs.

Avail the Discount on this Report: https://dataintelo.com/ask-for-discount/?reportId=80747

The Stem Cell Therapy for Osteoarthritis Market Report Addresses:

The Report Provides:

Purchase Full Report: https://dataintelo.com/checkout/?reportId=80747

About US:

DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry.

Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact US:

Name Alex Mathews Phone No.: +1 909 545 6473 Email: [emailprotected] Website: https://dataintelo.com Address: 500 East E Street, Ontario, CA 91764, United States.

Originally posted here:
Global Stem Cell Therapy for Osteoarthritis Industry 2020 Market Research With Size, Growth, Manufacturers, Segments And 2026 Forecasts Research - The...

Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I – BioSpace

BOSTON and LONDON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to OTL-203, an investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy in development for the treatment of mucopolysaccharidosis type I (MPS-I) at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.

We are encouraged by EMAs decision to grant PRIME designation to OTL-203, which was based on an initial clinical assessment of data supporting the potential benefit of our HSC gene therapy for patients with MPS-IH beyond the current standard of care, said Anne Dupraz-Poiseau, PhD., chief regulatory officer of Orchard. In 2021, we look forward to building upon the promising early data in the ongoing proof-of-concept study and plan to initiate a registrational trial to advance a potential new treatment for patients.

The PRIME program is designed to enhance regulatory support in the EU for the development of promising investigational medicines that, based on early clinical data, may offer a major therapeutic advantage over existing treatments or benefit patients without treatment options. PRIME aims to provide multiple benefits so that these medicines can reach patients earlier: enhanced interaction and early dialogue with EMA, guidance on the overall development plan and regulatory strategy, and the potential for accelerated assessment of the marketing authorization application. For more information please visit the EMA website at http://www.ema.europa.eu.

Additional interim data was recently presented from the ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203 in the severe Hurler subtype of MPS-I. Eight patients have been treated in the study, which completed enrollment in December 2019. As of July 2020, all patients had been followed for a minimum of six months, with the longest follow-up extending out to 24 months. Orchard expects to release full proof-of-concept results at one year and initiate a registrational study for OTL-203 in 2021.

About OTL-203 and MPS-I

Mucopolysaccharidosis type I (MPS-I) is a rare, inherited neurometabolic disease caused by a deficiency of the alpha-L-iduronidase (IDUA) lysosomal enzyme, which is required to break down sugar molecules called glycosaminoglycans (also known as GAGs). The accumulation of GAGs across multiple organ systems results in symptoms including neurocognitive impairment, skeletal deformity, loss of vision and hearing, and cardiovascular and pulmonary complications. MPS-I occurs at an overall estimated frequency of one in every 100,000 live births. There are three subtypes of MPS-I; approximately 60 percent of children born with MPS-I have the most severe subtype, called Hurler syndrome, and rarely live past the age of 10 when untreated. Treatment options for MPS-I include hematopoietic stem cell transplant and chronic enzyme replacement therapy, both of which have significant limitations. Though early intervention with enzyme replacement therapy has been shown to delay or prevent some clinical features of the condition, it has only limited efficacy on neurological symptoms. OTL-203 is an investigational ex vivo autologous hematopoietic stem cell gene therapy being studied for the treatment of MPS-I. Orchard was granted an exclusive worldwide license to intellectual property rights to research, develop, manufacture and commercialize the gene therapy program for the treatment of MPS-I developed by the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy.

About Orchard

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

Availability of Other Information About Orchard

Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-Looking Statements

This press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as anticipates, believes, expects, plans, intends, projects, and future or similar expressions that are intended to identify forward-looking statements. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, the therapeutic potential of Orchards product candidates, including the product candidate referred to in this release, Orchards expectations regarding the timing of clinical trials for its product candidates, including the product candidate referred to in this release, the timing of interactions with regulators and regulatory submissions related to ongoing and new clinical trials for its product candidates, the timing of announcement of clinical data for its product candidates, and the likelihood that such data will be positive and support further clinical development and regulatory approval of these product candidates. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development, its supply chain and commercial programs; the risk that Orchard will not realize the anticipated benefits of its new strategic plan or the expected cash savings associated with such plan; the risk that any one or more of Orchards product candidates, including the product candidate referred to in this release, will not be successfully developed, approved or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates or that long-term adverse safety findings may be discovered; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; and the risk of delays in Orchards ability to commercialize its product candidates, if approved. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards quarterly report on Form 10-Q for the quarter ended June 30, 2020, as filed with the U.S. Securities and Exchange Commission (SEC), as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts

Investors Renee Leck Director, Investor Relations +1 862-242-0764 Renee.Leck@orchard-tx.com

Media Molly Cameron Manager, Corporate Communications +1 978-339-3378 media@orchard-tx.com

Original post:
Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I - BioSpace

Stem Cell Therapy Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 – The Daily Chronicle

Allosource

The report provides comprehensive analysis in an organized manner in the form of tables, graphs, charts, pictures and diagrams. Organized data paves the way for research and exploration of current and future market outlooks.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=33553

The report provides comprehensive data on the Stem Cell Therapy market and its trends to help the reader formulate solutions to accelerate business growth. The report provides a comprehensive overview of the economic scenario of the market, as well as its benefits and limitations.

The Stem Cell Therapy Market Report includes production chain analysis and value chain analysis to provide a comprehensive picture of the Stem Cell Therapy market. The research consists of market analysis and detailed analysis of application segments, product types, market size, growth rates, and current and emerging industry trends.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

Request customization of the report @https://reportsglobe.com/need-customization/?rid=33553

The market is geographically spread across several key geographic regions and the report includes regional analysis as well as production, consumption, revenue and market share in these regions for the 2020-2027 forecast period. Regions include North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Radical Coverage of the Stem Cell Therapy Market:

Key Questions Addressed in the Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-stem-cell-therapy-market/

Thanks for reading our report. It is possible to adapt this report to the wishes of the customer. Contact us to learn more about the report and our team will make sure you create a report based on your needs.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

Read more:
Stem Cell Therapy Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily Chronicle

Dr. Leslie on the Development of CAR T-Cell Therapy in DLBCL and MCL – OncLive

Lori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.

Lori A. Leslie, MD, a hematology/oncology specialist at John Theurer Cancer Center, discussesdevelopmentsin CAR T-cell therapy indiffuse large B-cell lymphoma (DLBCL)andmantle cell lymphoma (MCL).

A lot has been done with CAR T-cell therapy since the approval of axicabtagene ciloleucel (axi-cel; Yescarta) in 2017 for patients with relapsed/refractory DLBCL, says Leslie. Initial studies examined this approach in patients with DLBCL who were very refractory, were more appropriate for hospice than CAR T cells, and had aggressive lymphoma. Approximately 40% of patients experienced long-term complete remissions (CRs) or potential cure, which is impressive in a patient population that was expected to live less than 6 months, explains Leslie.

CAR T-cell therapy is moving earlier in the treatment journey for DLBCL. When a standard-of-care option is used, patients have usually received 2 prior lines of therapy, theyre not as refractory, and are in better shape to start CAR T-cell therapy; these patients have more flexibility to wait between T-cell collection and CAR T manufacturing, says Leslie.

Ongoing studies are looking at potentially replacing autologous stem cell transplant (ASCT) with CAR T cells, even in the second-line setting for patients who are at high risk of relapse within 1year of frontline therapy, adds Leslie. Trials are looking at randomizing patients to either CAR T-cell therapy or standard salvage ASCT in this setting. Similar studies are being conducted in the MCL space.

Development in low-grade lymphomas and MCL will be similar, Leslie adds. Brexucabtagene autoleucel (Tecartus; formerly KTE-X19) has been approved by the FDA for patients with relapsed/refractory MCL. Plans are underway to move this modality earlier on in the treatment journey, particularly in patients withp53-mutated abnormal MCL, blastoid MCL, orpleomorphic high-risk MCL. The goal is to eradicate minimal residual disease (MRD) after frontline treatment if patients do not experience an MRD-negative CR, says Leslie. Those are exciting research questions that will be answered in the near future, concludes Leslie.

Here is the original post:
Dr. Leslie on the Development of CAR T-Cell Therapy in DLBCL and MCL - OncLive

From artificial lenses to stem cell techniques: these are the most important innovations in ophthalmology – Innovation Origins

Our professional field is constantly evolving, says Professor Carroll Webers. He is head of the University Clinic for Ophthalmology at Maastricht UMC+ in the Netherlands, where he started in 1993 as an ophthalmologist with glaucoma (high eye pressure) as a special focus area. Since then, the field has been expanding rapidly and encompasses a wide range of applications for patients. Such as treatments for eye disorders caused by diabetes, retinal detachment, glaucoma, and macular degeneration (which is an age-related phenomenon that affects the retina).

Technological developments play a key role in what can be achieved in ophthalmology. Webers gives a brief glimpse into how the Maastricht university clinic is contributing to these developments.

Notably with the research on stem cell technique carried out by his colleague Professor Rudy Nuijts, for example. A technique that is especially interesting for people who have become blind in one eye as a result of a burn or a caustic substance in the eye.

Together with the Italian cell biologistGraziella Pellegrini and the company Chiesi Pharmaceuticals, Nuijts developed a technique whereby stem cells from the healthy eye are used to grow a new membrane. Nuijts extracts the stem cells which are then sent by courier to Italy. There, Pellegrini cultivates these cells, which takes about two weeks. After that, they are returned to the Maastricht UMC+ as a new membrane. Nuijts subsequently attaches this to the damaged eye. In the Dutch television program Dokters van Morgen (Doctors of Tomorrow), they show how Anne-Mieke King is able to see again after being blind in one eye for many years.

A groundbreaking innovation, Webers declares, but not one that many people will have to undergo. That certainly is the case for cataract operations. At a later age, plenty of peoples own lenses become cloudy, which is what we call a cataract. In the Netherlands, cataract surgery is carried out about 180,000 times a year. The blurred lens is then replaced by an artificial lens. Up until the 1990s, the incision had to be at least as large as the own lens, about 10 millimeters, and that had to be stitched up again. Webers: In general, the smaller the surgical procedure, the faster the patients recovery. With laser techniques, we only need an opening of 1.6 millimeters to replace the blurred lens. Because the incision is so small, stitches are no longer necessary.

I always joke with my patients by saying that both their eyes are about the same age. That implies that they have cataracts in both eyes. For years, the guideline was that one eye was operated on first and after two weeks, the other eye followed. Recently, the Maastricht UMC completed a study showing that it is possible to operate both eyes at once.

You first operate on one eye. Then you take a totally new set of instruments, new fluids, a new jacket, new gloves, and you operate on the other eye. Since July, patients can come to Maastricht UMC+ for this double-sided operation. This has been stepped up in part due to corona. Because in this corona crisis you naturally want patients to be hospitalized as little as possible. If you operate them separately on both eyes, they will just end up coming to the hospital twice as often.

Patients not only need to be examined less often, but it also makes a difference in terms of home care, Webers notes. After this kind of operation, patients have to have eye drops. A substantial proportion of this is done by home care services. Initially, patients have to get drops four times a day for a week, then three times a day for a week, then twice a day for a week, and then once a day for a week. If that can be done with two eyes at the same time, it would make a huge difference.

His original specialism, glaucoma, is also advancing. Every eye has a certain pressure by nature. An eye would never be a beautiful ball otherwise. With glaucoma, the pressure is in principle too much for that eye and in the long run, this leads to irreparable damage. In the end, the patient becomes visually impaired and blind.

There are approximately 350,000 people in the Netherlands who are walking around with glaucoma, Webers adds. High eye pressure can be treated with eye drops, laser surgery, and minor surgical procedures. But the real innovation is a very small stent, which you can also insert into a blood vessel. The hollow tube makes it easier for fluid to drain away, Webers goes on to explain. A project is being carried out by the University Clinic for Ophthalmology at Maastricht UMC+ in conjunction with the Brightlands Campus Chemelot. Ophthalmologist Henny Beckers is in charge of the project.

Finally, Webers goes on to talk a little about his hobby. You dont really know in advance how sensitive a patient is to that eye pressure. The problems only manifest themselves at a later stage. If I knew how sensitive someone is, I might or might not opt for a more intensive treatment. In order to gain more understanding of that sensitivity, the clinic collects body tissue from all glaucoma-compatible patients for research. Of course, we ask for permission to store blood and the tissue and fluid thats lost during surgery. The eye tissue bank now contains samples from around 1500 patients.

Webers explains that you can make blood cells, stem cells, and optic nerve cells from those stem cells. You have to do all sorts of things to achieve this. But it can be done. These cultivated optic nerve cells are put under pressure under laboratory conditions. We want to develop an instrument that allows us to show whether a patient is very sensitive to eye pressure or not. This will give us an insight into how great the risk is that that patient will become seriously visually impaired over the course of her or his life. Then you also have a better idea of how extensively you should treat them.

In addition to sensitivity, Webers also hopes to gain a deeper understanding of what the innate protective factors are. It could be your genes or your diet, for example. You could add protective substances to the cultivated optic nerve cells to see if that cell would then become less vulnerable, Webers continues. Those substances can vary a lot from one individual to another. You may be sensitive to all sorts of substances contained in green vegetables, whereas I am not at all. In that case, the advice would be: Take nutritional supplements. And for me: Dont do that. To us, this is Personalized Medicine. Highly innovative but still at an experimental stage.

This article is a follow-up to: Electronic lens offers a medical solution for eye disorders.

See the original post here:
From artificial lenses to stem cell techniques: these are the most important innovations in ophthalmology - Innovation Origins

The global market for Nerve Repair and Regeneration is projected to reach US$12.7 billion by 2025 – GlobeNewswire

September 29, 2020 02:35 ET | Source: ReportLinker

New York, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nerve Repair and Regeneration Devices Industry" - https://www.reportlinker.com/p05957490/?utm_source=GNW Nerves constitute the most significant cable systems in the human body, performing the crucial job of carrying messages and information to brain and also to other parts of body. Whenever such critical nerves are injured, problems arise in muscles leading to sensation loss. Major types of nerve injuries include Neuropraxia, the physiologic blocking of nerve; Axonotmesis, the anatomic disruption of axon with slight disruption of connective tissue; and Neurotmesis, the anatomic disruption of connective tissue and nerve fibers.These injuries could result in trauma or more serious neurodegenerative diseases such as Parkinson`s disease, Alzheimer`s disease, multiple system atrophy, multiple sclerosis, and amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig`s disease).Alzheimer`s, Parkinson`s, Amyotrophic Lateral Sclerosis and multiple sclerosis are diseases that cause injury to the complex, delicate structures of the nervous system.Till date spinal cord injury and peripheral nerve damage are often permanent and incapacitating.

Innovative strategies are required for a shift in the paradigm and advanced treatment of these neurological injuries.But the question as to whether adult neurogenesis isrealstill remains unanswered with several contentious research studies still underway with no definitive answer to this century-long debate. Regrowth or repair of nervous tissues and cells involves generation of new neurons, glia, axons, myelin, or synapses.Gene Therapy is attracting immense research investments for its promise in promoting nerve regeneration and intraneural revascularization is being studied for its role in peripheral nerve regeneration.Newer studies are however dampening hopes by stating that adults produce no new cells in the hippocampus. Nevertheless, hopes of regeneration arecreating lucrative commercial opportunities as the pressure builds for newer and more effective treatment for neurological diseases.As the world awaits for a paradigm-shift in the treatment of neurological injury, neurostimulation and neuromodulation devices and biomaterials remains a massive multi billiondollar market worldwide. Neurostimulation and neuromodulation devices are currently available solutions to treat a variety of nerve injuries including peripheral nerve injuries. Neurostimulation and neuromodulation methods involve use of specially designed devices to transmit electrical impulses for controlling activity of the central nervous system and the brain.Internal neurostimulation and neuromodulation devices are growing in popularity for their significantly lower risk for post-surgical complications and shorter hospital stays. These include deep brain stimulation (DBS)for Parkinson`s, epilepsy and depression; spinal cord stimulation (SCS) for pain management and spasticity; gastric electrical stimulation (GES) for obesity and gastroparesis; vagus nerve stimulation (VNS) for depression and epilepsy; and sacral nerve stimulation (SNS) for constipation and urinary incontinence disorders.External neurostimulation devices, on the other hand, comprise transcutaneous vagus nerve stimulation (TVNS) for autism, depression, anxiety and age related disorders; transcutaneous electrical nerve stimulation (TENS)for chronic neuropathic pain and fibromyalgia disorders; transcranial magnetic stimulation (TMS)for depression and ADHD; and respiratory electrical stimulation (RES) for improving the respiratory function after spinal cord injury.

Read the full report: https://www.reportlinker.com/p05957490/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW Nerve Repair and Regeneration Market Set for a Rapid Growth Neurostimulation and Neuromodulation Devices: Largest Product Segment Biomaterials to Exhibit Rapid Growth Nerve Repair and Regeneration Market by Application US and Europe Dominate the Market, Asia-Pacific to Register the Fastest Growth

2. FOCUS ON SELECT PLAYERS Abbott Laboratories, Inc. (USA) AxoGen, Inc. (USA) Boston Scientific Corporation (USA) Integra LifeSciences Corporation (USA) LivaNova, PLC (UK) Medtronic plc (USA) NeuroPace, Inc. (USA) Nevro Corporation.(USA) Orthomed S.A.S. (France) Polyganics B.V. (The Netherlands) Stryker Corporation (U.S.) Synapse Biomedical Inc. (U.S.)

3. MARKET TRENDS & DRIVERS High Incidence of Brain Disorders and Nerve Injuries: Primary Market Driver Annual Incidence of Adult-Onset Neurologic Disorders in the US Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy Global Alzheimers Prevalence by Age Group Diagnosed Prevalence Cases of Parkinson?s Disease Across Select Countries Classification of Nerve Injuries Recent Developments in Spinal Cord Injury Treatment Rising Geriatric Population and Subsequent Growth in Prevalence Of Neurological Disorders Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 Intensified Research Activity Across Various Neural Disciplines Induces Additional Optimism Stem Cell Therapy: A Promising Avenue for Nerve Repair and Regeneration New Biomaterials Pave the Way for Innovative Neurodegeneration Therapies Role of Nerve Conduits in the Treatment of Peripheral Nerve Injury Innovative Nerve Conduits from Stryker Technological Advancements and Product Innovations - A Key Growth Driver Neurostimulation Allows Paralyzed People to Regain Leg Movement Neurostimulator to Treat Neurological Conditions Micro-Implantable Solution for Neurostimulation Parasym? Device for Neurostimulation Boston Scientific?s Spinal Cord Stimulation Improves Quality of Life Intellis? Platform Presents Smallest Implantable Neurostimulator Innovation in Deep Brain Stimulation for Parkinson?s Disease Innovations in Spinal Cord Stimulation for Pain Smart Neuromodulation: The Combination of AI and Neuromodulation Technologies New Dynamic Lead Interface Design for Neurostimulator Devices Wireless SCS Neuromodulation Therapy: An Alternative to Traditional SCS System Select Recent Approvals of Neuro-stimulation and Neuromodulation Devices Select Launches in Spinal Cord Stimulation (SCS) Market Select Launches in Deep Brain Stimulation (DBS) Market Select Neurostimulation Devices in Clinical Trials Select Neuromodulation Devices in Clinical Trials

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Nerve Repair and Regeneration Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 2: World Historic Review for Nerve Repair and Regeneration Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 3: World 15-Year Perspective for Nerve Repair and Regeneration Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Neurostimulation & Neuromodulation Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 5: World Historic Review for Neurostimulation & Neuromodulation Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 6: World 15-Year Perspective for Neurostimulation & Neuromodulation Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Biomaterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 8: World Historic Review for Biomaterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 9: World 15-Year Perspective for Biomaterials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Neurostimulation & Neuromodulation Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 11: World Historic Review for Neurostimulation & Neuromodulation Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 12: World 15-Year Perspective for Neurostimulation & Neuromodulation Surgeries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Neurorrhaphy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 14: World Historic Review for Neurorrhaphy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 15: World 15-Year Perspective for Neurorrhaphy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Nerve Grafting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 17: World Historic Review for Nerve Grafting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 18: World 15-Year Perspective for Nerve Grafting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 20: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 21: World 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 23: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 24: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 26: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 27: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES Table 28: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 29: USA Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 30: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 31: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 32: USA Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 33: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 34: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 35: USA Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 36: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

CANADA Table 37: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 38: Canada Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 39: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 40: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 41: Canada Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 42: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 43: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 44: Canada Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 45: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

JAPAN Table 46: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 47: Japan Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 48: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 49: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 50: Japan Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 51: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 52: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 53: Japan Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 54: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

CHINA Table 55: China Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 56: China Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 57: China 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 58: China Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 59: China Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 60: China 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 61: China Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 62: China Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 63: China 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

EUROPE Table 64: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 65: Europe Historic Review for Nerve Repair and Regeneration Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 66: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 67: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 68: Europe Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 69: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 70: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 71: Europe Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 72: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 73: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 74: Europe Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 75: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

FRANCE Table 76: France Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 77: France Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 78: France 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 79: France Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 80: France Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 81: France 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 82: France Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 83: France Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 84: France 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

GERMANY Table 85: Germany Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 86: Germany Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 87: Germany 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 88: Germany Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 89: Germany Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Here is the original post:
The global market for Nerve Repair and Regeneration is projected to reach US$12.7 billion by 2025 - GlobeNewswire

Stem Cell Market By Applications, Types, New Technology Opportunity Analysis And Forecast: 2020 2028 – The Daily Chronicle

Latest Market Scenario for Stem Cell Market

The major objective of the report is to offer a complete evaluation of the Stem Cell market and crucial insights, historical data, industry-validated market data, facts, and policies with a suitable set of assumptions and methodology. The report also analyses the Stem Cell market in a dynamic structure by studying and identifying the market segments and forecast for the global market size. Click here to get sample of the premium report: https://www.quincemarketinsights.com/request-sample-40210?utm_source= dc/hp

In addition, the report emphasizes the competitive analysis of key players by-product, growth strategies, financial position, price, product portfolio, and regional existence. The report also offers PEST analysis, SWOT analysis, and PORTERs analysis to address the questions of shareholders.

Stem Cell Market

Global Stem Cell Market Size and Scope:

The global Stem Cell market is segmented by company, type, application, by region, by country, and by sales channels. Industry players, stakeholders, and other market contributors in the global market will be able to increase their efficiency, as they can use the analysis as a powerful resource. Moreover, the segmental analysis emphasizes on sales, revenue, and estimation by region, company, type, application, by country, and by sales channels for the period 2016-2028. The global Stem Cell market is segmented as By Source (Adult Stem Cell, Human Embryonic Cell, Pluripotent Stem Cell, and Others), By Application (Therapeutic and Drug Development and Discovery), By Treatment Type (Allogeneic, Autologous, and Syngeneic), By Stem Cell Banking (Service & Technology and Banking Type). In terms of geographical regions, the market is segregated into North America, Asia Pacific, Europe, and the Middle East and Africa and South America.

Get ToC for the overview of the premium report https://www.quincemarketinsights.com/request-toc-40210?utm_source=dc/hp

Competitive Scenario of the Global Stem Cell Market

The Stem Cell Market report presents several major manufacturers in the industry. The study offers a big microscopic look into the target industry. The reader can recognize the footprints of the industries by knowing the global market share of manufacturers, the global price of manufacturers, and sales by providers over the forecast period. It helps the client understand the strategies and acquisitions that providers can leverage in order to combat competition in the industry. The key players of the automotive automatic transmissions have been provided in the report. These include Thermo Fisher Scientific, Qiagen NV, Sigma Aldrich, Becton, Dickinson and Company, and Stem Cell Technologies

The Stem Cell Market is studied by market experts by keeping in mind how to boost the return on investment by offering clear data required for informed business decisions. It illuminates the competitive scenario, the supply and demand status, and the challenges for market growth, market opportunities, and the threats faced by the key players.

Speak to analyst before buying this report https://www.quincemarketinsights.com/enquiry-before-buying-40210?utm_source=dc/hp

The recent trends observed in the target market, owing to the emergence of advanced technologies implemented in the Stem Cell Market, have been studied in detail. This research will help both developed and novel competitors to identify and analyze market essentials, market size, and competition. The report evaluates the growth rate and the precise market value based on the growth-inducing factors and market dynamics. The complete knowledge is based on recent news, opportunities, and recent trends presented in the report.

Highlights Covered in Global Stem Cell Market Report:

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Read more from the original source:
Stem Cell Market By Applications, Types, New Technology Opportunity Analysis And Forecast: 2020 2028 - The Daily Chronicle